Monte Rosa Therapeutics (GLUE) Leases (2023 - 2025)
Monte Rosa Therapeutics' Leases history spans 3 years, with the latest figure at $24.4 million for Q4 2025.
- For Q4 2025, Leases fell 9.11% year-over-year to $24.4 million; the TTM value through Dec 2025 reached $24.4 million, down 9.11%, while the annual FY2025 figure was $24.4 million, 9.11% down from the prior year.
- Leases reached $24.4 million in Q4 2025 per GLUE's latest filing, down from $25.1 million in the prior quarter.
- In the past five years, Leases ranged from a high of $30.5 million in Q1 2023 to a low of $24.4 million in Q4 2025.
- Average Leases over 3 years is $27.6 million, with a median of $27.6 million recorded in 2024.
- Peak YoY movement for Leases: dropped 6.86% in 2024, then decreased 9.11% in 2025.
- A 3-year view of Leases shows it stood at $28.8 million in 2023, then dropped by 6.86% to $26.8 million in 2024, then dropped by 9.11% to $24.4 million in 2025.
- Per Business Quant, the three most recent readings for GLUE's Leases are $24.4 million (Q4 2025), $25.1 million (Q3 2025), and $25.7 million (Q2 2025).